Healthcare group AfroCentric reported a fall in profit and decided against rewarding shareholders as it felt the effects of various changes in the company, including restructuring, and declining demand for healthcare since the end of the Covid-19 pandemic.

“The trading in the pharmaceutical cluster has normalised back to pre-Covid levels and therefore decreasing from the high levels experienced in the June 2022 financial year which was driven by the Covid-19 impact,” the company valued at about R2.8bn on the JSE, said in its results for the year to end-June...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.